Cited by 843Lung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis

Open access

Lee, Chee Khoon, Man, Johnathan, Lord, Sally, Links, Matthew, Gebski, Val, Mok, Tony, Yang, James Chih-Hsin·2017·Journal of Thoracic Oncology

DOI 10.1016/j.jtho.2016.10.007

Open this paper in CoChat — free account Open PDF

Abstract

Introduction We performed a meta-analysis to assess the role of immune checkpoint inhibitors as second-line therapy in EGFR-mutant advanced NSCLC.Methods Randomized trials comparing immune checkpoint inhibitors against chemotherapy were identified. We retrieved the hazard ratio (HR) and 95% confidence interval (CI) for overall survival (OS) of the intention-to-treat population and EGFR mutation-defined subgroups. We used the fixed-effects inverse variance-weighted method to pool estimates of treatment efficacy. Statistical tests were two sided.Results In the three included studies that compared immune checkpoint inhibitors (nivolumab [n = 292], pembrolizumab [n = 691], and atezolizumab [n =144]) against docetaxel (n = 776), immune checkpoint inhibitors significantly prolonged OS over that with docetaxel overall (n = 1903, HR = 0.68, 95% CI: 0.61-0.77, p < 0.0001) and in the EGFR wild-type subgroup (n = 1362, HR = 0.66, 95% CI: 0.58-0.76, p < 0.0001) but not in the EGFR-mutant subgroup (n = 186, HR = 1.05, 95% CI: 0.70-1.55, p < 0.81; treatment-mutation interaction p = 0.03).Conclusion In EGFR-mutant advanced NSCLC, immune checkpoint inhibitors do not improve OS over that with docetaxel. Mechanisms of acquired resistance to first-line tyrosine kinase inhibitor therapy should be elucidated to guide selection of second-line treatment for these patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2016.10.007

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
Self-citation
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Gainor, J. F., Shaw, A. T., Sequist, L. V. D., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L. E., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,268
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,250
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y. Y., Spitzler, P. J., Melnick, M. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0108 · Cited by 710

Flagged first, then by citations

Show all 15 references

Sorted by citations

Items 101–200 of 843

Genomics and the History of Precision Oncology
Doroshow, D. B., & Doroshow, J. H. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.08.003 · Cited by 93
Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment
Gong, K., Guo, G., Beckley, N. A., Zhang, Y., Yang, X., Sharma, M., & Habib, A. A. (2020) · Neoplasia · doi:10.1016/j.neo.2020.12.006 · Cited by 86
Clinical applications of PD-L1 bioassays for cancer immunotherapy
Liu, D., Wang, S., & Bindeman, W. E. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0479-y · Cited by 86
Emerging biomarkers for immune checkpoint inhibition in lung cancer
Cyriac, G., & Gandhi, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.006 · Cited by 86
Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
Kelly, W., Shah, N. J., & Subramaniam, D. S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00208 · Cited by 86
Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients
Garassino, M. C., Gelibter, A. J., Grossi, F., Chiari, R., Parra, H. J. S., Cascinu, S., Cognetti, F., Turci, D., Blasi, L., Bengala, C., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.025 · Cited by 85
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar, S. R., Shum, E., Grello, C., Lau, S. C. M., & Velcheti, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877594 · Cited by 89
Immunotherapy for the First-Line Treatment of Patients with Metastatic Non–Small Cell Lung Cancer
Martínez, P., Peters, S., Stammers, T. A., & Soria, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3904 · Cited by 82
Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer
Shaurova, T., Zhang, L., Goodrich, D. W., & Hershberger, P. A. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00281 · Cited by 82
Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers: The eNRGy1 Global Multicenter Registry
Drilon, A. E. D. C., Duruisseaux, M., Han, J., Ito, M., Falcon, C. J., Yang, S., Murciano‐Goroff, Y. R., Chen, H., Okada, M., Molina‐Vila, M. Á., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03307 · Cited by 88
Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer
Blaquier, J. B., Ortiz‐Cuaran, S., Ricciuti, B., Mezquita, L., Cardona, A. F., & Recondo, G. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1912 · Cited by 82
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
Voong, K. R., Feliciano, J. L., Becker, D. J., & Levy, B. P. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.48 · Cited by 84
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H
Gubens, M. A., Sequist, L. V. D., Stevenson, J. P., Powell, S. F., Villaruz, L. C., Gadgeel, S. M., Langer, C. J., Patnaik, A., Borghaei, H., Jalal, S. I., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.015 · Cited by 82
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
Passiglia, F., Cappuzzo, F., Alabiso, O., Bettini, A. C., Bidoli, P., Chiari, R., Defferrari, C., Delmonte, A., Finocchiaro, G., Francini, G., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0234-3 · Cited by 81
Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials
Huang, Q., Zhang, H., Hai, J., Socinski, M. A., Lim, E. K. S., Chen, H., & Stebbing, J. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1396403 · Cited by 82
Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC)
Yoneda, K., Imanishi, N., Ichiki, Y., & Tanaka, F. (2018) · Journal of UOEH · doi:10.7888/juoeh.40.173 · Cited by 80
Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial
Ahn, M., Cho, B. C., Ou, X., Walding, A., Dymond, A. W., Ren, S., Cantarini, M., & Janne, P. A. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.01.012 · Cited by 80
Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas
Tsukita, Y., Fujino, N., Miyauchi, E., Saito, R., Fujishima, F., Itakura, K., Kyogoku, Y., Okutomo, K., Yamada, M., Okazaki, T., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0953-y · Cited by 82
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer
Bylicki, O., Paleiron, N., Margery, J., Guisier, F., Vergnenégre, A., Robinet, G., Auliac, J. B., Gervais, R., & CHOUAID, C. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0510-9 · Cited by 82
Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges
Li, S., Chen, J. Y., & Sun, Z. (2021) · 癌症：英文版 · doi:10.1002/cac2.12183 · Cited by 79
A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR -Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
Hayashi, H., Sugawara, S., Fukuda, Y., Fujimoto, D., Miura, S., Ota, K., Ozawa, Y., Hara, S., Tanizaki, J., Azuma, K., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3194 · Cited by 77
Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer
Sekine, K., Kanda, S., Goto, Y., Horinouchi, H., Fujiwara, Y., Yamamoto, N., Motoi, N., & Ohe, Y. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.08.012 · Cited by 78
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study
Blakely, C. M., Urisman, A., Gubens, M. A., Mulvey, C. K., Allen, G. M., SHIBOSKI, S. C., Rotow, J. K., Chakrabarti, T., Kerr, D. L., Aredo, J. V., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00071 · Cited by 78
Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval
Khozin, S., Carson, K. R., Zhi, J., Tucker, M., Lee, S. E., Light, D. E., Curtis, M. D., Bralic, M., Kaganman, I., Gossai, A., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0307 · Cited by 76
PD-1/PD-L1 Axis in Lung Cancer
Santini, F. C., & Hellmann, M. D. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000300 · Cited by 77
Predictors for Clinical Benefit of Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis
El-Osta, H. E., & Jafri, S. H. R. (2019) · Immunotherapy · doi:10.2217/imt-2018-0086 · Cited by 75
Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities
Parakh, S., Ernst, M., & Poh, A. R. (2021) · Cancers · doi:10.3390/cancers13246228 · Cited by 77
Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer
Boesch, M., Baty, F., Albrich, W. C., Flatz, L., Rodriguez, R., Rothschild, S. I., Joerger, M., Früh, M., & Brutsche, M. H. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1988403 · Cited by 75
Understanding EGFR heterogeneity in lung cancer
Passaro, A., Malapelle, U., Re, M. D., Attili, I., Russo, A., Guerini‐Rocco, E., Fumagalli, C., Pisapia, P., Pepe, F., Luca, C. D., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000919 · Cited by 75
Clinical trials of CAR-T cells in China
Liu, B., Song, Y., & Liu, D. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0535-7 · Cited by 73
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
Zhao, Y., He, Y., Wang, W., Cai, Q., Ge, F., Chen, Z., Zheng, J., Zhang, Y., Deng, H., Chen, Y., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00379-6 · Cited by 76
DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel
Takamochi, K., Takahashi, F., Suehara, Y., Sato, E., Kohsaka, S., Hayashi, T., Kitano, S., Uneno, T., Kojima, S., Takeuchi, K., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.05.016 · Cited by 72
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)
Dudnik, E., Bshara, E., Grubstein, A., Fridel, L., Shochat, T., Roisman, L. C., Ilouze, M., Rozenblum, A. B., Geva, S., Zer, A., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.044 · Cited by 71
Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing
Zhang, Y., Chang, L., Yang, Y., Fang, W., Guan, Y., Wu, A., Hong, S., Zhou, H., Chen, G., Chen, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0939-9 · Cited by 70
Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan
Morita, R., Okishio, K., Shimizu, J., Saito, H., Sakai, H., Kim, Y. H., Hataji, O., Yomota, M., Nishio, M., Aoe, K., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.11.014 · Cited by 70
The combination of checkpoint immunotherapy and targeted therapy in cancer
Karachaliou, N., Gonzalez-Cao, M., Sosa, A. E., Berenguer, J., Bracht, J. W. P., Ito, M., & Rosell, R. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.47 · Cited by 71
EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells
Yu, S., Sha, H., Qin, X., Chen, Y., Li, X., Shi, M., & Feng, J. (2020) · Oncogene · doi:10.1038/s41388-020-1182-y · Cited by 71
Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
Garinet, S., Laurent‐Puig, P., Blons, H., & Oudart, J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7060144 · Cited by 71
Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)
Sun, R., Hou, Z., Zhang, Y., & Jiang, B. (2022) · Oncology Letters · doi:10.3892/ol.2022.13528 · Cited by 77
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
Odogwu, L., Mathieu, L. N., Goldberg, K. B., Blumenthal, G. M., Larkins, E. A., Fiero, M. H., Rodríguez, L., Bijwaard, K. E., Lee, E. Y., Philip, R., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0425 · Cited by 68
Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors
Lau, S. C. M., Fares, A. F., Le, L. W., Mackay, K. M., Soberano, S., Chan, S. W. S., Smith, E. C., Ryan, M. I., Tsao, M., Bradbury, P. A., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.12.015 · Cited by 65
Gold nanoparticle enhanced detection of EGFR with a terahertz metamaterial biosensor
Liu, K., Zhang, R., Liu, Y., Chen, X., Li, K., & Pickwell‐MacPherson, E. (2021) · Biomedical Optics Express · doi:10.1364/boe.418859 · Cited by 64
Dysregulation of TFH-B-TRM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer
Cho, J.-W., Park, S., Kim, G., Han, H., Shin, S., Shin, S., Bae, Y., Park, S. Y., Ha, S., Lee, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26362-0 · Cited by 66
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients
Passiglia, F., Galvano, A., Castiglia, M., Incorvaia, L., Calò, V., Listì, A., Mazzarisi, S., Perez, A., Gallina, G., Rizzo, S., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919839928 · Cited by 65
Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade
Huemer, F., Lang, D., Westphal, T., Gampenrieder, S. P., Hutarew, G., Weiß, L., Hackl, H., Lamprecht, B., Rinnerthaler, G., & Greil, R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071014 · Cited by 68
Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer
Ray, K., Újvári, B., Ramana, V., & Donald, J. A. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.04.002 · Cited by 64
Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies
Khaddour, K., Jonna, S., Deneka, A. Y., Patel, J. D., Abazeed, M. E., Golemis, E. A., Borghaei, H., & Boumber, Y. (2021) · Cancers · doi:10.3390/cancers13133164 · Cited by 67
Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors
Rossi, S., Toschi, L., Castello, A., Grizzi, F., Mansi, L., & Lopci, E. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3802-5 · Cited by 64
The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer
Kaderbhaï, C., Tharin, Z., & Ghiringhelli, F. (2019) · Cancers · doi:10.3390/cancers11020201 · Cited by 63
Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer
Borcherding, N. C., Kolb, R. H., Gullicksrud, J. A., Vikas, P., Zhu, Y., & Zhang, W. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.030 · Cited by 60
Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
Santaniello, A., Napolitano, F., Servetto, A., Placido, P. D., Silvestris, N., Bianco, C., Formisano, L., & Bianco, R. (2019) · Cancers · doi:10.3390/cancers11101419 · Cited by 61
Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know
Camelliti, S., Noci, V. L., Bianchi, F., Moscheni, C., Arnaboldi, F., Gagliano, N., Balsari, A., Garassino, M. C., Tagliabue, E., Sfondrini, L., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01721-9 · Cited by 61
Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies
Noia, V. D., D’Aveni, A., D’Argento, E., Rossi, S., Ghirardelli, P., Bortolotti, L., Vavassori, V., Bria, E., & Ceresoli, G. L. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100280 · Cited by 60
Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions
Chen, K., Pan, G., Cheng, G., Zhang, F., Xu, Y., Huang, Z., & Fan, Y. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13748 · Cited by 59
Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC
Tian, Y., Zhai, X., Yan, W., Zhu, H., & Yu, J. (2020) · Cancer Medicine · doi:10.1002/cam4.3590 · Cited by 58
Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence
Huemer, F., Leisch, M., Geisberger, R., Melchardt, T., Rinnerthaler, G., Zaborsky, N., & Greil, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082856 · Cited by 60
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies
Hegde, A. M., Andreev-Drakhlin, A. Y., Roszik, J., Huang, L., Liu, S., Hess, K. R., Cabanillas, M. E., Hu, M. I.-N., Busaidy, N. L., Sherman, S. I., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000799 · Cited by 57
Targeting immune checkpoints in non small cell lung cancer
Bianco, A., Malapelle, U., Rocco, D., Perrotta, F., & Mazzarella, G. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.02.006 · Cited by 57
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan
Lin, S., Yang, C., Liao, B.-C., Ho, C., Liao, W., Chen, K., Tsai, T.-H., Hsu, C., Hsu, W., Su, K., et al. (2018) · Journal of Cancer · doi:10.7150/jca.24985 · Cited by 57
Self-citation
Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer
Watanabe, S., Hayashi, H., Haratani, K., Shimizu, S., Tanizaki, J., Sakai, K., Kawakami, H., Yonesaka, K., Tsurutani, J., Togashi, Y., et al. (2018) · Cancer Science · doi:10.1111/cas.13860 · Cited by 57
Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients
Hilke, F. J., Sinnberg, T. W., Gschwind, A., Niessner, H., Demidov, G. M., Amaral, T. M. S., Ossowski, S., Bonzheim, I., Röcken, M., Rieß, O., et al. (2020) · Cancers · doi:10.3390/cancers12092359 · Cited by 56
FAM111B, a direct target of p53, promotes the malignant process of lung adenocarcinoma
Sun, H., Liu, K., Huang, J., Sun, Q., Shao, C., Luo, J., Xu, L., Shen, Y., & Ren, B. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s190934 · Cited by 55
Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore
Li, R., Han, D., Shi, J., Han, Y., Tan, P., Zhang, R., & Li, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188420 · Cited by 57
Scientific Advances in Thoracic Oncology 2016
Soo, R. A., Stone, E. C. A., Cummings, K. M., Jett, J. R., Field, J. K., Groen, H. J. M., Mulshine, J. L., Yatabe, Y., Bubendorf, L., Đačić, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.019 · Cited by 55
Self-citation
Real-world Efficacy and Safety of Nivolumab for Advanced Non–Small-cell Lung Cancer: A Retrospective Multicenter Analysis
Kobayashi, K., Nakachi, I., Naoki, K., Satomi, R., Nakamura, M., Inoue, T., Tateno, H., Sakamaki, F., Sayama, K., Terashima, T., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.01.001 · Cited by 56
Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
Liang, H., Liu, X., & Wang, M. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s178497 · Cited by 55
New advances in immunotherapy for non-small cell lung cancer.
Qin, H., Wang, F., Liu, H., Zeng, Z., Wang, S., Pan, X. H., & Gao, H. (2018) · Europe PMC (PubMed Central) · Cited by 52
Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
Pu, X., Wu, L., Su, D., Mao, W., & Fang, B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4990-5 · Cited by 56
Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma
Chan, A. W. H., TONG, J. H. M., Kwan, J. S. H., Chow, C., Chung, L. Y., Chau, S. L., Lung, R. W. M., Ng, C. S. H., Wan, I. Y. P., Mok, T. S. K., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0053-3 · Cited by 51
Self-citation
Cisplatin Promotes the Efficacy of ICI Therapy by Inducing Ferroptosis and Activating Neutrophils
Zhou, Z., Zhao, Y., Chen, S. X., Cui, G., Fu, W., Li, S., Lin, X., & Hu, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.870178 · Cited by 51
Role of Osimertinib in the Treatment of EGFR-Mutation Positive Non-Small-Cell Lung Cancer
Carlisle, J. W., & Ramalingam, S. S. (2019) · Future Oncology · doi:10.2217/fon-2018-0626 · Cited by 50
Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up
Chalmers, A. W., Patel, S. B., Boucher, K. M., Cannon, L. A., Esplin, M., Luckart, J. B., Graves, N., Duren, T. V., & Akerley, W. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00658-0 · Cited by 50
Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance
Passarelli, A. M., Aieta, M., Sgambato, A., & Gridelli, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01479 · Cited by 50
DeePaN: deep patient graph convolutional network integrating clinico-genomic evidence to stratify lung cancers for immunotherapy
Fang, C., Xu, D. H., Su, J., Dry, J. R., & Linghu, B. (2021) · npj Digital Medicine · doi:10.1038/s41746-021-00381-z · Cited by 53
Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms
Suda, K., Rivard, C. J., Mitsudomi, T., & Hirsch, F. R. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1355243 · Cited by 49
Lung Cancer in Nonsmoking Individuals
Murphy, C., Pandya, T., Swanton, C., & Solomon, B. (2025) · JAMA · doi:10.1001/jama.2025.17695 · Cited by 55
Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
Remón, J., Hendriks, L. E. L., Cabrera, C., Reguart, N., & Besse, B. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.006 · Cited by 49
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection
Banna, G. L., Passiglia, F., Colonese, F., Canova, S., Menis, J., Addeo, A., Russo, A. D., & Cortinovis, D. L. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.016 · Cited by 48
Hypoalbuminaemia as a Prognostic Biomarker of First-Line Treatment Resistance in Metastatic Non-small Cell Lung Cancer
Stares, M. D., Swan, A. M., Cumming, K., Ding, T.-E., Leach, J., Stratton, C., Thomson, F., Barrie, C., Maclennan, K., Campbell, S., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.734735 · Cited by 47
KEYNOTE ‐025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1–positive advanced non–small‐cell lung cancer
Nishio, M., Takahashi, T., Yoshioka, H., Nakagawa, K., Fukuhara, T., Yamada, K., Ichiki, M., Tanaka, H., Seto, T., Sakai, H., et al. (2019) · Cancer Science · doi:10.1111/cas.13932 · Cited by 48
Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy
Ginefra, P., Lorusso, G., & Vannini, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124441 · Cited by 48
Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase
Orlando, E., Aebersold, D. M., Medová, M., & Zimmer, Y. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.12.001 · Cited by 46
Optimal management of EGFR -mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
Liao, B.-C., Lin, C., Lee, J., & Yang, J. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.05.009 · Cited by 48
Self-citation
Atezolizumab for the treatment of non-small cell lung cancer
Santini, F. C., & Rudin, C. M. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1356717 · Cited by 47
Possible Biomarkers for Cancer Immunotherapy
Otoshi, T., Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2019) · Cancers · doi:10.3390/cancers11070935 · Cited by 47
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
Nassar, A. H., Kim, S. Y., Aredo, J. V., Feng, J., Shepherd, F. A., Xu, C., Kaldas, D., Gray, J. E., Dilling, T. J., Neal, J. W., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.01.012 · Cited by 46
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker
Signorelli, D., Giannatempo, P., Grazia, G., Aiello, M. M., Bertolini, F., Mirabile, A., Buti, S., Vasile, E., Scotti, V., Pisapia, P., et al. (2019) · BioMed Research International · doi:10.1155/2019/9056417 · Cited by 47
MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer
Yoshida, R., Saigí, M., Tani, T., Springer, B. F., Shibata, H., Kitajima, S., Mahadevan, N. R., Campisi, M., Kim, W., Kobayashi, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0770 · Cited by 47
Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment
Qiu, J., Cheng, Z., Jiang, Z., Gan, L., Zhang, Z., & Xie, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105490 · Cited by 53
Treatment options for EGFR mutant NSCLC with CNS involvement—Can patients BLOOM with the use of next generation EGFR TKIs?
Tan, C., Cho, B. C., & Soo, R. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.012 · Cited by 45
Immune Checkpoint Blockade: The New Frontier in Cancer Treatment
Clarke, J. M., George, D. J., Lisi, S., & Salama, A. K. S. (2018) · Targeted Oncology · doi:10.1007/s11523-017-0549-7 · Cited by 45
Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions
Remón, J., Vilariño, N., & Reguart, N. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.002 · Cited by 45
Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti–Programmed Cell Death-1 Therapy in NSCLC
Ohue, Y., Kurose, K., Karasaki, T., Isobe, M., Yamaoka, T., Futami, J., Irei, I., Masuda, T., Fukuda, M., Kinoshita, A., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.008 · Cited by 45
STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer
Attili, I., Karachaliou, N., Bonanno, L., Berenguer, J., Bracht, J. W. P., Codony‐Servat, J., Codony, C., Ito, M., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918763744 · Cited by 45
Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells
Suda, K., Rozeboom, L. M., Rivard, C. J., Yu, H., Ellison, K. E., Melnick, M. A., Hinz, T. K., Chan, D. C. F., Heasley, L. E., Politi, K. A., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.04.010 · Cited by 42
Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients
Mei, T., Wang, T., & Zhou, Q. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01324-0 · Cited by 47
A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment
Chubachi, S., Yasuda, H., Irie, H., Fukunaga, K., Naoki, K., Soejima, K., & Betsuyaku, T. (2016) · Case Reports in Oncological Medicine · doi:10.1155/2016/1075641 · Cited by 44
Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?
Attili, I., Passaro, A., Pavan, A., Conte, P., de Marinis, F., & Bonanno, L. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.007 · Cited by 45
Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients
Mitsuhashi, A., & Okuma, Y. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1827-7 · Cited by 43

Authors: Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H.
Affiliations: The University of Sydney (AU)
St George Hospital (AU)
Chinese University of Hong Kong (HK)
National Taiwan University (TW)
Corresponding author: Lee, Chee Khoon
ORCID: Lee, Chee Khoon
Man, Johnathan
Links, Matthew
Gebski, Val
Mok, Tony
Yang, James Chih-Hsin
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2017-02
Volume: 12
Issue: 2
Pages: 403-407
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1016/j.jtho.2016.10.007
OpenAlex: W2538232731
Cited by: 839
References: 15
Citations by year: 2026: 47 · 2025: 61 · 2024: 68 · 2023: 84 · 2022: 93 · 2021: 98 · 2020: 100 · 2019: 100 · 2018: 123 · 2017: 62
FWCI: 85.21
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
Locations: Journal of Thoracic Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: immune checkpoint inhibitors, EGFR-mutant non-small cell lung cancer, second-line therapy, nivolumab, pembrolizumab, atezolizumab, docetaxel, overall survival, advanced non-small cell lung cancer
MeSH terms: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Immunotherapy, Lung Neoplasms, Mutation, Prognosis, Randomized Controlled Trials as Topic, Cell Cycle Checkpoints, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks